Tentative Beijing debt deal is a relief for Colombo
Beijing is the island's largest bilateral lender, and its consent is needed for any proposal by Colombo to reorganise its finances
By Eastern EyeOct 18, 2023
SRI LANKA last Wednesday (11) welcomed China’s tentative agreement to a debt restructure, as the island nation works to restore its finances after suffering its worst-ever economic crisis.
The government defaulted on its $46 billion (£37.7bn) debt last year at a time when months of food and fuel shortages were making life a misery for Sri Lanka’s 22 million people.
Beijing is the island’s largest bilateral lender, and its consent is needed for any proposal by Colombo to reorganise its finances.
Ranjith Siyambalapitiya, the deputy finance minister, said approval had now been granted by the state-owned Export-Import Bank of China, its official creditor.
“China has issued their primary consent to restructure our debt,” he said in a statement.
The Chinese foreign ministry spokesman Wang Wenbin told reporters last Tuesday (10) that the bank had “tentatively agreed” with Sri Lanka on its debt treatment in late September.
“We are also glad to see other creditors are having discussions with Sri Lanka as well over solutions to its debt issue,” he added.
Neither party shared further details of the agreement.
China holds about 52 per cent of the south Asian nation’s bilateral credit, with Japan and India the next-biggest lenders.
Beijing had, in March, given in-principle agreement to a restructure of its loans to Sri Lanka, the final major creditor to do so.
That decision cleared the way for a staged $2.9bn (£2.37bn) International Monetary Fund (IMF) bailout, conditional on austerity measures such as tax hikes and cuts to public subsidies.
But a second tranche of $330 million (£270m) was delayed last month, with the IMF saying it was still reviewing “financing assurances” from creditors on the detailed debt restructure plan Colombo proposed in June.
Sri Lanka’s central bank governor Nandalal Weerasinghe was last week in Morocco for a meeting with creditor nations and the IMF that does not include China.
The IMF’s Sri Lanka mission chief, Peter Breuer, said the lender had “not yet been informed about any specific agreements” with creditors, Bloomberg reported.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.